Healthcare, Pharma & Life Sciences

United States – October 27, 2026 -- An analysis of 5,723 patients on Foundayo (oral orforglipron) found that 40.3% had no evidence of prior GLP-1 medication use, according to Truveta, which is pitching real-time "healthcare intelligence" to life science, healthcare and government teams.

Foundayo uptake runs mostly through primary care

Truveta researchers used Truveta Data to identify patients with a Foundayo prescription or medication dispense between April 1 and July 6, 2026. The drug was approved for obesity in April 2026.

General practice clinicians accounted for 60.0% of prescriptions, and advanced practice providers for another 31.9%. Only 0.1% of patients had evidence of recent oral semaglutide use.

United States – October 27, 2026 -- Computer-assisted navigation was used in 41.0% of endoscopic sinus surgeries in 2026, up from 29.2% in 2018, a 40.4% relative increase, according to a Truveta Data analysis of adult patients.

Navigation used in 35.5% of 98,971 procedures over the study period

The analysis covered endoscopic sinus surgeries performed between January 1, 2018, and August 31, 2026. Visits within 90 days of a prior surgery code were counted as a single procedure. Navigation was identified through a specific add-on CPT code.

United States – October 27, 2026 -- Robotic assistance in total knee arthroplasty (TKA) rose from 12.4% of procedures in 2018 to 36.1% in 2026, a 191% relative increase, according to an analysis of 362,667 procedures in Truveta Data.

Robotic assistance was used in 24.3% of all procedures in the study period, which ran from January 2018 to August 2026. Robotic-assisted cases ran longer. Median operation time was 136 minutes (IQR 116-160), against 126 minutes (IQR 109-149) without robotics.

Seattle – October 27, 2026 -- Truveta has secured a place on LinkedIn's 2026 Top Startups list for Seattle, its fourth consecutive year on the ranking. The annual list covers emerging companies in the Seattle region that are attracting talent, growing quickly and building momentum.

Truveta employs more than 500 people globally

The company said its headcount now exceeds 500 worldwide. It credits the Greater Seattle area's talent pool and entrepreneurial base for shaping the business from the start, and says it plans to keep building a culture around its health mission as it grows.

LinkedIn ranks startups on four hiring and engagement pillars

LinkedIn compiles the list from proprietary platform data. It scores companies on employment growth, engagement, job interest and the attraction of top talent.

Global – October 27, 2026 -- The Truveta Genome Project aims to build the largest and most diverse de-identified database of exome-wide genomic data linked to high-fidelity clinical data ever assembled, according to a statement from a Truveta executive who joined the company earlier this year.

Health systems founded Truveta during the pandemic to speed up learning

Leading health systems created Truveta during the global pandemic around one premise: healthcare should learn faster. Patient experiences, clinical insights and research findings are meant to feed a shared resource rather than stay siloed within single institutions.

Europe – October 27, 2026 -- Continuous glucose monitoring (CGM) was associated with a 45% lower risk of death at one year among adults with type 2 diabetes on basal insulin, according to a study presented at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting.

The analysis used Truveta Data to track nearly 28,000 adults with type 2 diabetes receiving basal insulin therapy. Researchers combined longitudinal electronic health record (EHR) and mortality data in a target trial emulation that compared CGM users with non-users.

CGM users show 36% lower two-year mortality risk

At one year, CGM users had a 45% lower risk of death from any cause than non-users. At two years, the reduction was 36%.

United States – October 27, 2026 -- Truveta aims to enroll tens of millions of consenting participants in the Truveta Genome Project. The goal is the largest and most diverse database of genotypic and phenotypic information ever assembled, according to Kristin Rand, the company's Senior Director of Genomics Partnerships.

The project has moved from planning to enrolling participants and collecting samples, roughly 15 months after Truveta announced it. It builds a consented, de-identified genomic dataset linked with longitudinal clinical data, treatments and outcomes. Truveta has not disclosed current enrollment figures or the number of participating health systems.

PONTE VEDRA – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has agreed to raise $3 million in gross proceeds from a single healthcare-focused institutional investor. Warrants could bring in about $5.8 million more if exercised in full for cash.

Cadrenal prices 960,000 shares at $3.125 with two warrant series attached

The private placement covers 960,000 common shares, or pre-funded warrants in lieu, at a combined price of $3.125 per share with accompanying warrants. The deal is priced at-the-market under Nasdaq rules. Each unit carries series C-1 and series C-2 warrants, each series covering up to 960,000 shares at a $3.00 exercise price. H.C. Wainwright & Co. is exclusive placement agent. Closing is expected on or about July 1, 2026, subject to customary conditions.

PARIS – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reported that its 12-lipoxygenase inhibitor CAD-1005 reduced new or worsening thrombotic events by more than 25 percentage points versus placebo in a Phase 2 trial in heparin-induced thrombocytopenia (HIT), with 50% of treated patients affected versus more than 75% on placebo. The data were presented as one of three late-breaking abstracts at the ISTH 2026 Congress in Paris.

Trial is first randomized, blinded, placebo-controlled study in HIT

Principal Investigator Dr. Steven E. McKenzie delivered the oral presentation, which Cadrenal describes as the first randomized, blinded, placebo-controlled trial in HIT patients. CAD-1005 was formerly known as VLX-1005. The study was not sufficiently powered for statistical significance.

Ponte Vedra, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has launched a structured process to secure out-licensing, portfolio monetization or co-development partners for its late-stage cardiovascular assets, after grouping them into a Cardiac Acute Critical Care Franchise.

The company is exploring development, licensing and commercialization deals for CAD-1005, frunexian and tecarfarin. It describes the approach as capital-efficient and says it is shifting to a partnership-driven business model.